Send to:

Choose Destination
See comment in PubMed Commons below
An Pediatr (Barc). 2014 Apr;80(4):259.e1-23. doi: 10.1016/j.anpedi.2013.04.013. Epub 2013 Oct 10.

[Prevention of serogroup B meningococcal disease using a four-component vaccine].

[Article in Spanish]

Author information

  • 1Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Madrid, España. Electronic address:
  • 2Técnico de Salud Pública, Madrid, España.
  • 3Especialista en Medicina Preventiva y Salud Pública, Barcelona, España.
  • 4Servicio de Medicina Preventiva, Centro de Vacunación de Adultos, Hospital Clínic, Barcelona, España.
  • 5Servicio de Medicina Preventiva y Epidemiología, Hospital Vall d'Hebron, Barcelona, España.
  • 6Centro de Salud Pasai San Pedro, Pasaia, Gipuzkoa, España.
  • 7Especialista en Medicina Preventiva y Salud Pública, Valencia, España.
  • 8Unidad de Cuidados Intensivos Pediatría, Hospital Clínico Universitario de Santiago, Universidad de Santiago de Compostela, Santiago de Compostela, España.
  • 9Unidad de Enfermedades Infecciosas y Tropicales Pediátricas, Servicio de Pediatría, Hospital Carlos III, Madrid, España.
  • 10Unidad de Infectología Pediátrica, Hospital Materno-Infantil Carlos Haya, Málaga, España.
  • 11Servicio de Medicina Preventiva, Complexo Hospitalario Universitario de Ourense, Orense, España.
  • 12Laboratorio de Referencia de Meningococos, Instituto de Salud Carlos III, Madrid, España.

Erratum in

  • An Pediatr (Barc). 2014 Apr;80(4):273-4.



Meningococcal disease is an infection caused by Neisseria meningitidis, and those of serogroup B are currently the most predominant. It has been difficult to create effective vaccines for this serogroup in order to modify or reduce its morbidity. The aim of this study was to review existing data on the new vaccine 4CMenB and its potential contribution to the prevention of this infection.


A panel of 12 experts (from Pediatrics, Public Health and Vaccinology) conducted a literature search and prioritized 74 publications. A review of the vaccine was then prepared, which was discussed in a meeting and subsequently validated by e-mail.


4CMenB vaccine, based on four components (NadA, fHbp, NHBA and OMVnz), was designed by reverse vaccinology. The Meningococcal Antigen Typing System (MATS) shows a potential of 70-80% coverage of the strains in Europe. Clinical trials show that the vaccine is safe and immunogenic in infants, children, adolescents, and adults, and induces an anamnestic response. The incidence of fever is similar to systemic vaccines administered alone, but higher when co-administered with them, although the fever pattern is predictable and self-limited. It is compatible with the Spanish routine vaccines, and can be administered simultaneously with the currently available hexavalent and pentavalent vaccines, as well as the pneumococcal conjugate vaccine.


The 4CMenB vaccine is the only strategy currently available to prevent meningococcal disease caused by serogroup B.

Copyright © 2013 Asociación Española de Pediatría. Published by Elsevier Espana. All rights reserved.


Meningitis; Meningitis meningocócica; Meningococcal; Meningococcal vaccines; Prevención y control mesh terms; Prevention and control [subheading]; Vaccines; Vacunas; Vacunas antimeningocócicas

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ediciones Doyma, S.L.
    Loading ...
    Write to the Help Desk